BioNexus Gene Lab Gross Profit

BioNexus Gene Lab posts a gross profit of $390K as of June 2026. That compares with $1.3M in the prior-year period — down 71.4% year over year. That is below the sector sector average of $790M. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, BioNexus Gene Lab's gross profit was $1.3M. The latest reading is $390K — a 71.4% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a gross profit near $790M is typical. BioNexus Gene Lab's $390K is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Gross Profit is one piece of BioNexus Gene Lab's financial statement story. At $390K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BGLC's gross profit usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $790M), and (3) consistency with growth and profitability. This page covers the first two; BioNexus Gene Lab's other metric pages and overview cover the third.